https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Optimal single 3T MR imaging sequence for HDR brachytherapy of cervical cancer https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20618 Wed 11 Apr 2018 16:49:52 AEST ]]> Validation of an MRI-only planning workflow for definitive pelvic radiotherapy https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48126  99% for criteria of 3%/2 mm and 2%/2 mm. With dose criteria of 1%/1 mm, the pass rate was higher for the male cohort at 96.3% than the female cohort at 93.4%. MRI to sCT anatomical agreement for bone and body delineated contours was assessed, with a resulting Dice score of 0.91 ± 0.2 (mean ± 1 SD) and 0.97 ± 0.0 for the male cohort respectively; and 0.96 ± 0.0 and 0.98 ± 0.0 for the female cohort respectively. The mean absolute error in Hounsfield units (HUs) within the entire body for the male and female cohorts was 59.1 HU ± 7.2 HU and 53.3 HU ± 8.9 HU respectively. Conclusions: A multi-atlas based method for sCT generation can be applied to a standard T1-weighted MRI sequence for male and female pelvic patients. The implications of this study support MRI only planning being applied more broadly for both male and female pelvic sites.]]> Tue 21 Mar 2023 15:07:30 AEDT ]]> Implications for dosimetric changes when introducing MR-guided brachytherapy for small volume cervix cancer: a comparison of CT and MR-based treatments in a single centre https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20297 cc for OAR and D₁₀₀, D₉₈ and D₉₀ for HR-CTV) were also considered. For patients with small HR-CTV sizes, introduction of MR-based volumetric brachytherapy produced a change in dose delivered to Point A and OAR. Point A doses fell by 4.8 Gy (p = 0.0002) and ICRU and D2cc doses for OAR also reduced (p < 0.01). Mean Point A doses for MR-based brachytherapy treatment plans were closer to those of HR-CTV D₁₀₀ for volumes less than 20 cm³ and HR-CTV D₉₈ for volumes between 20 and 35 cm³, with a significant difference (p < 0.0001) between Point A and HR-CTV D₉₀ doses in these ranges. In order to maintain brachytherapy dose consistency across varying HR-CTV sizes there must be a relationship between the volume of the HR-CTV and the prescription dose. Rather than adopting a ‘one size fits all’ approach during the transition to volume-based prescriptions, this audit has shown that separating prescription volumes into HR-CTV size categories of less than 20 cm³, between 20 and 35 cm³, and more than 35 cm³ the HR-CTV can provide dose uniformity across all volumes and can be directly linked to traditional Point A prescriptions.]]> Sat 24 Mar 2018 07:55:14 AEDT ]]> Viscous Aqueous Gel Illustrating Natural Anatomy: The VAGINA method in gynaecological MRI simulation https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55766 Fri 21 Jun 2024 08:26:52 AEST ]]>